Filing Details

Accession Number:
0000899243-20-001533
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-21 18:17:34
Reporting Period:
2020-01-16
Accepted Time:
2020-01-21 18:17:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631650 Aimmune Therapeutics Inc. AIMT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1488637 T. Douglas Sheehy Aimmune Therapeutics, Inc.
8000 Marina Boulevard, Suite 300
Brisbane CA 94005-1884
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2020-01-16 400 $12.95 46,068 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2020-01-16 400 $37.00 45,668 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-01-16 400 $0.00 400 $12.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
53,249 2026-04-29 No 4 M Direct
Footnotes
  1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
  2. Includes 29,617 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
  3. Includes 12,500 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
  4. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 4, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with Issuer on each such vesting date.